Terms: = Bone cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K
979 results:
1. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
[TBL] [Abstract] [Full Text] [Related]
2. RUNX1-BMP2 promotes vasculogenic mimicry in laryngeal squamous cell carcinoma via activation of the pi3k-AKT signaling pathway.
Zhu Q; Zhang X; Lu F; Miao S; Zhang C; Liu Z; Gao Z; Qi M; An X; Geng P; Wang S; Ren H; Han F; Zhang R; Zha D
Cell Commun Signal; 2024 Apr; 22(1):227. PubMed ID: 38610001
[TBL] [Abstract] [Full Text] [Related]
3. Exosome miR-101-3p derived from bone marrow mesenchymal stem cells promotes radiotherapy sensitivity in non-small cell lung cancer by regulating DNA damage repair and autophagy levels through EZH2.
Sun H; Zhu R; Guo X; Zhao P; Zhang R; Zhao Z; Zhou H
Pathol Res Pract; 2024 Apr; 256():155271. PubMed ID: 38574630
[TBL] [Abstract] [Full Text] [Related]
4. Lapatinib antitumor effect is associated with pi3k and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
5. Microbiome Dysbiosis Is Associated with Castration Resistance and cancer Stemness in Metastatic Prostate cancer.
Uzelac M; Xin R; Ongkeko WM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
[TBL] [Abstract] [Full Text] [Related]
6. USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the pi3k/AKT signaling pathway.
Li A; Wang S; Nie J; Xiao S; Xie X; Zhang Y; Tong W; Yao G; Liu N; Dan F; Shu Z; Liu J; Liu Z; Yang F
Cell Death Dis; 2024 Mar; 15(3):235. PubMed ID: 38531846
[TBL] [Abstract] [Full Text] [Related]
7. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (pi3k)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
8. Hydroxychloroquine interaction with phosphoinositide 3-kinase modulates prostate cancer growth in bone microenvironment: In vitro and molecular dynamics based approach.
Abdullah KM; Sharma G; Qais FA; Khan I; Takkar S; Kaushal JB; Kanchan RK; Sarwar T; Chakravarti B; Siddiqui JA
Int J Biol Macromol; 2024 May; 266(Pt 1):130912. PubMed ID: 38513896
[TBL] [Abstract] [Full Text] [Related]
9. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.
Mohan CD; Shanmugam MK; Gowda SGS; Chinnathambi A; Rangappa KS; Sethi G
Phytomedicine; 2024 Jun; 128():155379. PubMed ID: 38503157
[TBL] [Abstract] [Full Text] [Related]
10. Mefenamic acid exhibits antitumor activity against osteosarcoma by impeding cell growth and prompting apoptosis in human osteosarcoma cells and xenograft mice model.
Ye J; Chang T; Zhang X; Wei D; Wang Y
Chem Biol Interact; 2024 Apr; 393():110931. PubMed ID: 38423378
[TBL] [Abstract] [Full Text] [Related]
11. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
[TBL] [Abstract] [Full Text] [Related]
12. Role of PAX6, TRPA1, BCL11B, MCOLN2, CUX1, EMX1 in colorectal cancer and osteosarcoma.
Zhang J; Gao Q; Hou S; Chi X; Zheng M; Zhang Q; Shan H; Zhang X; Kang C
Medicine (Baltimore); 2024 Feb; 103(5):e37056. PubMed ID: 38306561
[TBL] [Abstract] [Full Text] [Related]
13. Exploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology and
Pang H; Wu H; Zhan Z; Wu T; Xiang M; Wang Z; Song L; Wei B
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186298
[TBL] [Abstract] [Full Text] [Related]
14. Identification and characterization of extrachromosomal circular DNA in age-related osteoporosis.
Zhu Q; Chen R; Kuang M; Zhang W; Wang D; Han S
Aging (Albany NY); 2023 Dec; 15(24):15489-15503. PubMed ID: 38159253
[TBL] [Abstract] [Full Text] [Related]
15. Solute carrier family 35 member A2 regulates mitophagy through the pi3k/AKT/mTOR axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.
Luo X; Zhang J; Guo C; Jiang N; Zhang F; Jiao Q; Xu K; Yang J; Qu G; Lv XB; Zhang Z
Gene; 2024 Mar; 898():148110. PubMed ID: 38151177
[TBL] [Abstract] [Full Text] [Related]
16. Caulis Spatholobi extracts inhibit osteosarcoma growth and metastasis through suppression of CXCR4/pi3k/AKT signaling.
Jiang Y; Gao Y; Li X; He F; Liu Y; Wang R
J Orthop Surg Res; 2023 Dec; 18(1):985. PubMed ID: 38129870
[TBL] [Abstract] [Full Text] [Related]
17. Exploration in the Mechanism of Ginsenoside Rg5 for the Treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.
Liu MY; Jiang DX; Zhao X; Zhang L; Zhang Y; Liu ZD; Liu RZ; Li HJ; Rong XY; Gao YZ
Orthop Surg; 2024 Feb; 16(2):462-470. PubMed ID: 38086608
[TBL] [Abstract] [Full Text] [Related]
18. Novel Pathways between Invasiveness Modulators in Breast cancer Single Cells.
Eliceiri GL
Crit Rev Eukaryot Gene Expr; 2024; 34(2):73-75. PubMed ID: 38073443
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive clinical, genome and transcriptomic analysis of primary ghost cell odontogenic carcinoma.
Zhang L; Xu Q; Feng Z
Oral Oncol; 2024 Jan; 148():106616. PubMed ID: 37988836
[TBL] [Abstract] [Full Text] [Related]
20. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
[TBL] [Abstract] [Full Text] [Related]
[Next]
